Hironobu Hashimoto

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Hironobu Hashimoto, Masakazu Abé, Osamu Tokuyama et al. · The Lancet Oncology · 2019 · 218 citations

Drug Safety, Chemotherapy-induced Nausea, Pharmacology +7

Hinge Sugar as a Movable Component of an Excimer Fluorescence Sensor

Hideya Yuasa, Naofusa Miyagawa, Takuhiro Izumi et al. · Organic Letters · 2004 · 134 citations

Synthesis of salacinol

Hideya Yuasa, Jun‐ichi Takada, Hironobu Hashimoto · Tetrahedron Letters · 2000 · 81 citations

Pharmacology, Synthetic Chemistry, Bioorganic Chemistry +1

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy

Takako Yanai, Satoru Iwasa, Hironobu Hashimoto et al. · International Journal of Clinical Oncology · 2017 · 71 citations

Oncology, Pharmacology, Emetogenic Cisplatin-based Chemotherapy +5

Oxidative Removal of <i>N</i>-(4-Methoxybenzyl) Group on 2,5-Piperazinediones with Cerium(IV) Diammonium Nitrate

Masanori Yamaura, Tsuneji Suzuki, Hironobu Hashimoto et al. · Bulletin of the Chemical Society of Japan · 1985 · 60 citations